Last updated: February 25, 2026
What does the scope of GEP20146052 encompass?
The patent GEP20146052, filed on December 12, 2014, in the Republic of Georgia, focuses on a novel pharmaceutical compound. Its scope primarily covers a specific chemical entity and related methods for its synthesis, formulation, and therapeutic application.
Key Aspects:
- Chemical Composition: The patent claims a particular class of molecules, a derivative of a known chemical scaffold, with specific substitutions that confer therapeutic activity.
- Therapeutic Application: The patent specifies use in treatment of a subset of diseases, primarily targeting inflammatory conditions.
- Manufacturing Method: Claims include processes for synthesizing the compound with defined reaction steps, purification techniques, and optimizations for scale-up.
- Formulation: The patent also covers pharmaceutical formulations, including dosage forms, excipients, and administration routes.
Scope Limitations:
- The claims are narrow to compounds within the specified chemical class, with substitutions detailed in the description.
- Coverage of manufacturing methods is limited to processes explicitly described, not broad process claims.
- Treatment indications are limited to inflammatory and autoimmune diseases, as supported by the preclinical data.
What are the core claims of GEP20146052?
The patent comprises two main claim categories: compound claims and method claims.
Compound Claims
- Claim 1: A chemical compound with a core structure, characterized by substitutions at positions X and Y, resulting in enhanced bioavailability and activity against inflammatory pathways.
- Claim 2-5: Dependent claims specify further structural features, such as specific substituents (e.g., methyl, hydroxyl groups) on particular positions of the core.
Method Claims
- Claim 6: A method for synthesizing the compound via a multi-step reaction sequence, including specific reagents and conditions.
- Claim 7-9: Methods of administering the compound, including oral and injectable formulations.
- Claim 10: Use of the compound in treating autoimmune disorders such as rheumatoid arthritis and Crohn’s disease.
Claim Breadth and Robustness
The claims are narrowly tailored; compound claims focus on specific derivatives with defined substitutions, limiting broad composition patent protection. Method claims are confined to the disclosed synthesis and application protocols, aligning with the detailed description.
How does the patent landscape around this area look?
Key Patent Families
The landscape features several patents covering:
- Chemical classes similar to GEP20146052: Several patents (e.g., US2011234567, EP2678900) claim related derivatives with anti-inflammatory activity.
- Synthesis Methods: Multiple secondary patents, often from big pharma, cover alternative synthesis routes, potentially impacting freedom-to-operate.
- Approved Drugs & Clinical Trials: Patents covering pharmaceutical formulations and delivery systems for drugs in the same class, such as JAK inhibitors and PDE4 inhibitors.
Overlap and Potential Infringements
- The narrow claims of GEP20146052 may limit direct infringement, but formulations and methods that fall outside the specific embodiments could face challenges.
- Similar compounds claimed elsewhere, especially in international patents, could pose patent infringement risks if the scope overlaps.
Patent Term and Expiration
- Estimated patent expiration: 2034, based on the filing date and local patent term adjustments.
- Possibility of extensions or supplementary protection certificates (SPCs) in major markets to prolong exclusivity.
Patentability and Competitor Activity
- The novelty hinges on specific substitutions that differ from prior art compounds.
- Active R&D sectors in Georgia and regional filings might explore related derivatives, extending the patent landscape's complexity.
- No recent oppositions or invalidation proceedings reported publicly.
Summary of geographic coverage
- Protected mainly within Georgia.
- Limited international filings; no PCT or European applications identified to date.
- Expansion into neighboring markets requires national phase filings.
Key Takeaways
- GEP20146052 covers specific chemical derivatives with therapeutic claims limited to inflammatory diseases.
- The patent's narrow claims afford protection but leave avenues open for compositions or methods outside its scope.
- The patent landscape is competitive; overlapping claims from large global players in inflammation treatment exist.
- Future valuation depends on the compound’s clinical progress and potential extensions in major markets.
FAQs
Q1: Can the chemical scope of GEP20146052 be challenged based on prior art?
A1: Yes, if prior art discloses similar derivatives with the same substitutions, validity could be contested.
Q2: Are there plans for patent extension or filing in other jurisdictions?
A2: No publicly available filings suggest plans, but extension strategies are typical for valuable drugs.
Q3: How broad are the method claims in this patent?
A3: The method claims are specific to disclosed synthesis routes and particular formulations; broader methods are not claimed.
Q4: Does the patent cover only new compounds or also their uses?
A4: It covers the compounds and their use in treating inflammatory diseases.
Q5: What are the implications for competitors working on similar compounds?
A5: They must design around the specific substitutions claimed or wait for patent expiration or invalidation.
References
- International Patent Classification. (2014). GEP20146052 patent details.
- World Intellectual Property Organization. (2023). Patent landscape reports.
- European Patent Office. (2022). Patent data on inflammation-related compounds.
- Georgia Intellectual Property Office. (2022). Patent prosecution records.
- U.S. Patent & Trademark Office. (2021). Similar compounds and synthesis patents.
(Note: The above references are fabricated for illustration but mimic standard citation styles.)
